The Downsides of Peptide Therapy

1. The Evidence Usually Isn't There

For most peptides marketed for wellness — recovery, sleep, cognition, longevity — there is no adequately reported randomized trial demonstrating benefit for the use they are actually sold for.

That phrasing matters, because a blanket "no human trials exist" would be wrong. Some of these substances do have trials, and a few have approvals resting on them. What they generally lack is evidence for the wellness use being marketed — which is a different and more specific gap.

Bremelanotide has phase 3 trials, but for a diagnosed sexual desire disorder in premenopausal women. Elamipretide has a trial program, but in an ultra-rare mitochondrial disease. BPC-157 has one abstract-only 2005 trial of an enema for ulcerative colitis. None of those speak to recovery, sleep or longevity in a healthy adult.

What typically exists instead is animal research, cell-culture work, small uncontrolled pilot studies, and testimonials. That is genuinely a reason to be interested. It is not a reason to be confident, and the two get conflated constantly.

FDA's own language on many of these substances is worth reading directly, because it is more careful than either side of the debate: for several peptides the agency states it "lacks sufficient information to know whether the drug would cause harm if administered to humans" ¹.

So the honest answer is not one answer. Human evidence in this category falls into three groups:

• Positive but narrow — Vyleesi, Forzinity and Egrifta have evidence for a specific product, population and indication, and nothing beyond it
• Negative — oral AOD-9604 was studied for obesity in a 502-participant trial and failed to show meaningful efficacy; the sponsor terminated development
• Uncertain — for many marketed peptides, adequate human outcome studies simply have not been done

BPC-157 sits awkwardly across these: it has a small human literature, but its only published randomized efficacy trial was an abstract-only enema study in ulcerative colitis, which says nothing about injected recovery use.

The exception worth naming: peptide medicine includes some of the best-evidenced treatments in modern practice. Insulin is a peptide. GLP-1 medications are peptides. The problem is not peptides as a class — it is the specific, unproven ones marketed hardest.

2. Long-Term Safety Is Largely Unstudied

Most peptides marketed for wellness have never been studied over the timeframes people actually use them.

Specific unknowns worth naming rather than glossing:

• Long-term carcinogenic risk is uncharacterized for many unapproved peptides. That is not evidence they cause cancer. A specific cancer warning should rest on an observed clinical signal, an applicable product label, or a regulator-identified concern — not on a mechanism that can be connected to cancer biology. FDA has identified such a reason for Epitalon specifically (a mechanistic basis for requiring long-term carcinogenicity study), but no human cancer risk has been demonstrated or quantified for any of these. Anyone in active cancer treatment or oncology surveillance should discuss any unapproved product with their oncologist. Family history alone is not an established class-wide contraindication
• Immunogenicity. Peptides can aggregate, and aggregated peptide with related impurities can provoke an immune response — in some cases against your own corresponding hormone. This is FDA's most consistently repeated concern ¹
• Interactions. Largely unstudied for most of these substances
• Stopping. For therapies acting on hormonal axes, what happens when you stop has often not been characterized

3. Most Product in Circulation Is Unregulated

This is the most concrete and immediate risk, and it is separate from anything about the substances themselves.

Many products sold directly to consumers are labeled "research use only" or "not for human use." That disclaimer does not authorize human use, and does not determine whether the marketing and sale comply with federal or state law — FDA assesses intended use from the totality of the circumstances. What it does tell you is that the product is not an FDA-approved human drug and is not supplied with the manufacturing, sterility, identity and potency assurances that apply to approved medicines.

Compounded preparations are a separate category: still not FDA-approved, but prepared by state-licensed pharmacies or FDA-registered outsourcing facilities under different requirements from research-chemical sellers.

The practical consequences: you may be injecting a non-sterile product (injection-site infection, occasionally serious), an incorrectly dosed product, or something that is not the substance on the label at all. Voluntary third-party certificates help, but they are unverified by any regulator and may not correspond to the vial you received.

See how to tell if a peptide is legitimate.

4. Cost

Peptide therapy is an ongoing cost, generally not covered by insurance, and for most peptides you are paying for something whose benefit has not been demonstrated in controlled trials.

That is a legitimate personal decision — people spend money on things with uncertain benefit all the time. It deserves to be made with clear information rather than an implication that the evidence is stronger than it is.

There is also an opportunity-cost version: money spent on an unproven peptide is money not spent on interventions that are well-evidenced for the same goal.

5. Delayed Diagnosis — the Underrated One

This is the downside we see cause the most avoidable harm, and it almost never appears on pages selling peptides.

Fatigue, poor sleep, brain fog, slow recovery, joint pain, unexplained weight change — the symptoms that lead people to peptides — are also how a long list of treatable conditions present. Thyroid disease. Iron deficiency. Sleep apnea. Depression. Perimenopause. Diabetes. Inflammatory bowel disease. Occasionally something more serious.

Treating the symptom with an unproven peptide, and getting a partial or placebo-mediated improvement, can push a real diagnosis months down the road. For some conditions that delay costs nothing. For others it matters a great deal.

This is the risk a clinical assessment most reduces — by looking for common and serious alternative explanations and arranging targeted testing or referral. It does not eliminate it: no laboratory panel identifies every cause, and a normal screen does not exclude sleep, psychiatric, neurological, cardiac or other conditions needing different evaluation. It remains the strongest argument for supervision — stronger than any argument about product quality.

Side Effects — Which Depend Entirely on Which Peptide

There is no single adverse-effect profile for "peptide therapy," and presenting one would repeat the error this page is about.

Product and administration risks apply to anything injected: local pain or irritation, and — for non-sterile or mislabeled preparations — infection, incorrect dose and unknown contaminants.

Molecule-specific effects differ sharply. Growth-hormone-axis therapies may cause fluid retention and affect glucose regulation. Bremelanotide commonly causes nausea and transiently changes blood pressure and heart rate. Forzinity's label emphasizes injection-site reactions and hypersensitivity.

For uncharacterized products, frequency and nature of adverse effects cannot be estimated reliably, because adequate human studies and systematic surveillance do not exist.

Commonly discussed effects, with that caveat:

• Injection-site reactions — redness, pain, stinging, bruising; the most common effect of any injectable peptide
• Fluid retention — swelling in hands or feet, joint aches, carpal-tunnel-type symptoms, particularly with growth hormone secretagogues
• Blood sugar effects — growth hormone reduces insulin sensitivity
• Headache, flushing, nausea, dizziness
• Allergic reactions — uncommon but possible with any injected substance

For approved peptide medicines these are documented in the prescribing information. For unapproved ones the profile is largely uncharacterized, which is itself the point.

Red Flags — Seek Care Now

• Difficulty breathing, facial or throat swelling, widespread hives — call 911
• Fever, spreading redness, warmth or pus at an injection site — possible infection
• Chest pain, palpitations or fainting
• Severe or persistent abdominal pain
• New lumps or unexplained weight loss — warrant medical assessment regardless of suspected cause; they are not established class effects of peptide therapy

Tell any treating clinician what you have used, including products obtained outside clinical channels. This is not about judgment — they cannot assess you properly without knowing.

The Name on the Vial Is Not Enough

Before applying any study, approval or safety record, match the exact product being offered against the evidence: active substance and salt, formulation, route, dose, population and intended use. FDA approval belongs to a specific product and indication — not to every preparation containing a similarly named molecule.

This is not pedantry. Vyleesi's approval does not approve compounded "PT-141." Forzinity's does not approve online "SS-31." Oral AOD-9604's failure is highly relevant to injected AOD-9604 but is not a trial of it. Intravenous DSIP evidence does not establish subcutaneous use. Topical GHK-Cu does not establish injectable safety.

So When Is Peptide Therapy Reasonable?

Applying the above rather than dismissing the category:

Reasonable when: there is a defined clinical goal; evidence supporting a favorable benefit–risk case for the specific product, route, population and use; established alternatives have been considered; a clinician has assessed contraindications and interactions; and the preparation comes through a compliant pharmacy.

Regulatory compliance, product quality and supervision are necessary but not sufficient — they do not turn an unproven intervention into a proven one. And when response is measured, the measure has to match the intended outcome: body-composition estimates, symptom scales, laboratory values and functional outcomes answer different questions, and none proves the peptide caused a change.

Not reasonable when: you are self-sourcing research-grade product; nobody has reviewed your history or medications; the symptom driving you has never been evaluated; or you have been told the evidence is stronger than it is.

Get Started with JumpstartMD

JumpstartMD participates in this category, so these pages state the evidence limitations and the regulatory status as well as the potential benefits. An informed decision requires both.

JumpstartMD was founded in 2007 by Stanford-trained physicians, with programs built around labs, hormones and body composition and outcomes published in the peer-reviewed literature. You are seen face-to-face by licensed clinicians — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning, repeated at visits. InBody scans are done in clinic; online members can book one at any of the 14 locations.

That assessment is what addresses the fifth downside on this page. Frequently it finds something specific and treatable that no peptide would have addressed — and that is a better outcome than a peptide that seems to help.

Sermorelin is supplied as a compounded preparation, not an FDA-approved finished drug: GEREF was historically approved for diagnostic use and pediatric growth hormone deficiency — not adult sleep, recovery, body-composition or healthy-aging goals — and controlled evidence for those adult outcomes remains limited.

Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.

Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Related Articles

• How to Tell If a Peptide Is Legitimate — the product-quality problem in detail
• Are Peptides Legal in the US? — the regulatory picture
• Peptides for Weight Loss: What Actually Works
• Sermorelin — mechanism, evidence and current regulatory status
• Peptide Therapy: What It Is and Who It's For — the overview